---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-031719"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:03:29.462219+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine Q1 net loss $49.1M; progress on Wilson, AATD programs

## Summary
- Net loss of $49.1M in Q1 2026 vs $51.9M in Q1 2025; R&D down to $34.1M.
- Cash position $149.2M as of March 31, 2026, providing runway into 2027.
- On track to file IND/CTA for PM577 (Wilson Disease) in H1 2026 and PM647 (AATD) mid-2026.
- Appointed Svetlana Makhni as CFO in April 2026; regulatory dialogue ongoing for PM359 BLA.
- Initial clinical data from PM577 and PM647 expected in 2027.

## SEC filing metadata
- accession: 0001628280-26-031719
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828026031719/0001628280-26-031719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828026031719/prme-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-031719
- JSON: https://secwatch.observer/filing/0001628280-26-031719.json
- Plain text: https://secwatch.observer/filing/0001628280-26-031719.txt

## Source-grounded claims
- claim_id: 39f4c15f7bc468f238d8934dabb8b2868f921d8c
  claim: Prime Medicine, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $49.1 million for the three months ended March 31, 2026.
  evidence_excerpt: Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2026 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000162828026031719/0001628280-26-031719-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.